X4P 001

Drug Profile

X4P 001

Alternative Names: AMD-070; AMD11070; X4P 001 RD; X4P-001-IO; X4P001

Latest Information Update: 18 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnorMED
  • Developer X4 Pharmaceuticals
  • Class Antineoplastics; Benzimidazoles; Diamines; Hydroquinones; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Immunodeficiency disorders
  • Phase II Renal cell carcinoma
  • Phase I/II Malignant melanoma
  • Phase I Solid tumours
  • Discontinued HIV-1 infections

Most Recent Events

  • 11 Dec 2017 Interim efficacy and adverse events data from a phase II/III trial Immunodeficiency disorders (WHIM Syndrome) presented at the 59th Annual Meeting of the American Society for Haematology (ASH-2017)
  • 16 Nov 2017 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Late-stage disease, Neoadjuvant therapy) in USA (PO) (NCT02823405)
  • 16 Nov 2017 Phase-I/II clinical trials in Malignant melanoma (Late-stage disease, Monotherapy, Neoadjuvant therapy) in USA (PO) (NCT02823405)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top